ArticleScientific reports2025
Mycobacterium hainanense sp. nov. represents an emerging nontuberculous Mycobacterium associated with chronic pulmonary disease.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Nontuberculous mycobacteria (NTM) are increasingly recognized as important opportunistic pathogens, particularly in immunocompromised individuals. We discovered a newly identified NTM, initially misidentified as Mycobacterium paraffinicum, isolated from a 42-year-old female with an eight-year history of persistent pulmonary infection. The pathogen shares high molecular similarities with Mycobacterium paraffinicum, Mycobacterium nebraskense, and Mycobacterium scrofulaceum, exhibiting atypical acid-fast properties and slow growth. Phylogenetic analysis and pairwise comparisons based on digital DNA-DNA hybridization and average nucleotide identity suggest it as a new species, which we propose naming it Mycobacterium hainanense sp. nov.. Significant differences were also observed in the 16 S rRNA, hsp65, rpoB, and sodA gene sequences between Mycobacterium hainanense and closely related mycobacterial species, confirming it as a novel species. Clinical, radiological, and microbiological findings, along with the patient's response to a tailored antibiotic regimen, are analyzed to understand disease progression and evaluate treatment efficacy against this newly identified pathogen. Functional genomic analysis highlighted diverse metabolic pathways, including lipid and carbohydrate metabolism, indicating the strain's ability to adapt to varying nutrient conditions and environmental stress. This study highlights the need for accurate identification of Mycobacterium species and calls for further in-depth research on the pathogenic mechanisms of Mycobacterium hainanense.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.